AgomAb Therapeutics NV (AGMB) vs Eupraxia Pharmaceuticals (EPRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Eupraxia Pharmaceuticals is the larger company by market cap ($492.9 million vs $447.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGMB | EPRX |
|---|---|---|
| Share price | $9.08 | $7.46 |
| Market cap | $447.17M | $492.91M |
| 1-day change | -1.52% | -1.45% |
| YTD return | — | -1.19% |
| 1-year return | — | +20.52% |
| EPS (TTM) | $-2.08 | $-1.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.82 | $9.32 |
| 52-week low | $7.97 | $5.25 |
| Distance from 52-week high | -49.05% | -19.96% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +314.87% | +119.17% |
| Average volume | 140.06K | 587.71K |
| Shares outstanding | 49.25M | 66.07M |
| Employees | 62 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Pharmaceuticals and Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AgomAb Therapeutics NV
AGMB stock →AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 62 employees
About Eupraxia Pharmaceuticals
EPRX stock →Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.
Health Care · Pharmaceuticals and Biotechnology · 49 employees
AGMB vs EPRX FAQ
Which is bigger, AgomAb Therapeutics NV or Eupraxia Pharmaceuticals?
Eupraxia Pharmaceuticals (EPRX) is larger, with a market capitalization of $492.91M compared with $447.17M for AgomAb Therapeutics NV (AGMB).
Are AgomAb Therapeutics NV and Eupraxia Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for AgomAb Therapeutics NV and Pharmaceuticals and Biotechnology for Eupraxia Pharmaceuticals.